tiprankstipranks
Trending News
More News >
Proto Labs Inc. (PRLB)
NYSE:PRLB

Proto Labs (PRLB) AI Stock Analysis

Compare
958 Followers

Top Page

PRLB

Proto Labs

(NYSE:PRLB)

Select Model
Select Model
Select Model
Outperform 72 (OpenAI - 5.2)
Rating:72Outperform
Price Target:
$60.00
▲(10.40% Upside)
Action:ReiteratedDate:02/07/26
The score is driven primarily by strong financial resilience (near-zero leverage and solid cash generation). Technicals support the uptrend, but an overbought RSI increases near-term risk. Valuation is the largest constraint due to the very high P/E and no dividend support, while earnings-call guidance and commentary are constructive but tempered by Europe weakness, margin pressure in the network business, and ongoing transformation costs.
Positive Factors
Balance sheet strength
Proto Labs' negligible leverage and substantial cash provide durable financial flexibility: supports investment in production expansion, funds transformation initiatives, enables buybacks or opportunistic M&A, and buffers cyclical demand swings without forcing distress-driven financing over the next 2–6 months.
Reliable cash generation
Consistent operating and free cash flow underpins capital allocation optionality: supports shareholder returns, funds ISO/capacity investments, and finances the 2026 transformation. Even with a recent FCF dip, cash conversion remains solid, sustaining strategic investments without raising new leverage.
Factory margin & capability gains
Improving factory margins and certifications (ISO 13485) strengthen higher-margin, in-house production capacity, enabling durable expansion into regulated medical and aerospace end-markets. This structural shift supports margin sustainability and higher revenue per customer over the medium term.
Negative Factors
Europe revenue weakness
Sustained weakness in Europe signals structural demand or execution issues in a major region; the need for a regional reset and cost realignment could depress growth and delay returns on investments in that market, constraining consolidated revenue expansion in the medium term.
Network margin pressure
Reliance on a distributed partner network exposes Proto Labs to tariffs, logistics and operational inefficiencies that compress network margins. Persistent network margin headwinds limit overall margin recovery and make scaling low-volume fulfillment structurally less profitable unless operational fixes are realized.
Modest growth & below-peak margins
Revenue growth remains modest and margins haven't returned to prior peak levels, indicating limited operating leverage. This structural constraint reduces free-cash-flow upside and slows path to the company's $1B revenue/margin objectives absent sustained demand or margin recovery initiatives.

Proto Labs (PRLB) vs. SPDR S&P 500 ETF (SPY)

Proto Labs Business Overview & Revenue Model

Company DescriptionProto Labs, Inc., together with its subsidiaries, operates as an e-commerce driven digital manufacturer of custom prototypes and on-demand production parts in the worldwide. The company offers injection molding; computer numerical control machining; three-dimensional (3D) printing, which include stereolithography, selective laser sintering, direct metal laser sintering, multi jet fusion, polyjet, and carbon DLS processes; and sheet metal fabrication products, including quick-turn and e-commerce-enabled custom sheet metal parts. It serves developers and engineers, who use 3D computer-aided design software to design products across a range of end markets. The company was incorporated in 1999 and is headquartered in Maple Plain, Minnesota.
How the Company Makes MoneyProto Labs makes money primarily by charging customers for the manufacturing of custom parts and related services. Revenue is generated on a per-order basis when customers upload CAD files, receive pricing/lead-time quotes, and place orders for parts produced using Proto Labs’ in-house manufacturing capabilities (notably injection molding, CNC machining, and 3D printing). In addition, the company earns revenue by fulfilling orders through its distributed manufacturing network, where it coordinates production with third-party manufacturing partners and captures value by providing customer acquisition, automated quoting, program management, quality/inspection expectations, and logistics while paying partner suppliers for fabrication. Key drivers of earnings include order volume, average order value (influenced by part complexity, material selection, finishing requirements, and tolerances), lead-time/expedite choices, and the mix between in-house manufacturing versus network-fulfilled work. Significant contributing factors also include the company’s digital sales channel and automated quoting workflow, which reduce friction for customers and can increase conversion and repeat usage for prototyping and bridge/low-volume production programs.

Proto Labs Key Performance Indicators (KPIs)

Any
Any
Revenue by Geography
Revenue by Geography
Breaks down revenue across different regions, revealing where Proto Labs is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Chart InsightsProto Labs' U.S. revenue shows robust growth, highlighted by a 30% rise in CNC machining, despite tariff challenges. In contrast, European revenue faces a 15% decline due to contracting manufacturing activity. Japan's revenue remains stagnant, indicating a strategic focus shift. The company's strong cash position and shareholder returns underscore resilience, but the European downturn and declines in injection molding and 3D printing pose risks. Future growth hinges on balancing these challenges with the successful expansion of high-demand segments like CNC machining.
Data provided by:The Fly

Proto Labs Earnings Call Summary

Earnings Call Date:Feb 06, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:May 01, 2026
Earnings Call Sentiment Positive
The earnings call conveyed a broadly positive outlook driven by record quarterly and annual revenue, strong CNC and factory margin performance, improved revenue per customer, solid cash generation, and concrete strategic moves (ISO 13485, India GCC, product and e‑commerce initiatives). However, the company faces notable near-term challenges — a material decline in Europe, pressure on network margins (tariffs/inefficiencies), declines in injection molding and 3D printing prototyping demand, and short-term operating and transformation costs. Management framed 2026 as a year of transformation intended to drive sustained, higher growth and margin expansion, and provided modest 6–8% revenue guidance while investing to scale long-term initiatives.
Q4-2025 Updates
Positive Updates
Record Quarterly and Annual Revenue
Fourth quarter revenue was a company record of $136.5M, up 11% year over year in constant currencies; full year 2025 revenue was $533.1M, up 5.7% year over year in constant currencies.
Improved Revenue per Customer / Contact
Revenues per customer grew 13% in 2025, and management noted revenue per contact accelerated ~23% in Q4, demonstrating success in increasing share of wallet from existing customers.
Strong CNC and Sheet Metal Demand
CNC machining saw robust growth: overall CNC revenue grew 16.7% year over year and U.S. CNC revenue grew 25% in 2025 (U.S. CNC +35% in Q4). Sheet metal revenue grew 12% year over year. Management cited strong demand from drones, satellites, rockets, robotics and other aerospace/defense end markets.
High and Improving Factory Margins
Fourth quarter non-GAAP gross margin was 44.8%, up 140 basis points year over year. Full year factory non-GAAP gross margin was 49%, up 70 basis points year over year, driven by volume growth and factory productivity improvements.
Network and Factory Revenue Mix Strength
Proto Labs network revenue grew 13.8% for the year while factory revenue also grew; fourth quarter revenue fulfilled to network was $30.5M, up 11.2% in constant currencies, showing balance between factory and network channels.
Cash Generation and Balance Sheet Strength
Generated $74.5M in cash from operations in 2025, returned $43M to shareholders via repurchases, and ended the year with $142.4M in cash and investments and zero debt.
Certifications and Production Capability Expansion
Achieved ISO 13485 certification for U.S. factory injection molding (medical device production requirement) and initiated pilots with two medical device customers for high-precision production volumes — a key enabler for expanding production revenue.
2026 Growth Guidance and Strategic Plan
Management expects 2026 GAAP revenue growth of 6–8% and provided Q1 revenue guidance of $130M–$138M (midpoint implies ~6% growth). Company outlined four strategic pillars (customer experience, innovation, production expansion, operational efficiency) and reiterated a long-term path toward $1B revenue and margin expansion.
Negative Updates
Decline in Europe Revenue
Europe revenue declined 8.1% in Q4 (constant currencies) and 7% for the full year, prompting a regional reset with go-to-market changes and cost structure realignment to address underperformance.
Weakness in Injection Molding and 3D Printing
Injection molding revenue declined 1.9% for the year (hit by weakness in medical device and lower prototyping demand). 3D printing revenue declined 4.7% year over year due to weak prototype demand for plastic parts and older technologies (though metal 3D printing DMLS saw double-digit growth in the U.S.).
Network Gross Margin Pressure
Network non-GAAP gross margin fell ~190 basis points year over year to ~31% (Q4 network margin 30.3%), attributed largely to inefficiencies related to tariffs and network fulfillment complexities.
Rising Operating Expenses and Short-Term Charges
Q4 non-GAAP operating expenses increased $5.2M year over year (driven by higher incentive compensation, commissions, and medical expenses). Full year non-GAAP operating expenses were $193.3M (36.3% of revenue vs. 36.0% prior year). Management also expects transformation and restructuring costs (noted ~$0.7M add-back) as part of 2026 changes.
Softness/Normalizing Demand Early in 2026
Management noted a typical post-holiday normalization in January and implied Q1 may be softer sequentially despite Q4 strength; the guidance cadence reflects a year of transformation rather than immediate step-change acceleration.
Decline in Unique Buyers / Contacts
Investor questions noted unique developers/contacts were down to the lowest level in a while; management emphasized focus on revenue per contact but acknowledged the need to grow both contacts and revenue per contact over time.
Company Guidance
Proto Labs guided full-year 2026 GAAP revenue growth of 6–8% and gave Q1 2026 revenue guidance of $130–$138 million (midpoint implying roughly 6% year‑over‑year growth), with a ~$2.1 million favorable foreign‑currency impact versus 2025; they expect Q1 non‑GAAP EPS of $0.36–$0.44 and disclosed full‑year non‑GAAP assumptions including stock‑based compensation ≈ $3.6M, amortization ≈ $0.9M, transformation and restructuring costs ≈ $0.7M, and a non‑GAAP effective tax rate of 24–25%.

Proto Labs Financial Statement Overview

Summary
Strong overall fundamentals led by an exceptionally low-debt balance sheet and solid operating/free cash flow. Profitability has recovered since 2022, but revenue growth is modest and margins remain below 2020–2021 levels, limiting the score.
Income Statement
68
Positive
PRLB’s profitability has recovered meaningfully from the 2022 loss year, with positive earnings in 2023–2024 and further improvement in TTM (Trailing-Twelve-Months) net margin (~4.0%) versus 2024 (~3.3%). Gross margin has remained fairly steady around the mid-40% range, supporting a solid baseline profitability profile. The key weakness is growth and margin momentum: revenue is only modestly higher in TTM (Trailing-Twelve-Months) (roughly +2.8%) after a flat 2024, and operating/EBITDA margins are still well below 2020–2021 levels—suggesting the business has not fully regained prior operating leverage.
Balance Sheet
90
Very Positive
The balance sheet is a major strength. Debt is extremely low (TTM (Trailing-Twelve-Months) debt-to-equity ~0.004), indicating minimal leverage risk and strong financial flexibility. Equity and assets are substantial and stable, and return on equity has moved back into positive territory in TTM (Trailing-Twelve-Months) (~3.1%) after the 2022 downturn. The primary drawback is that returns remain modest versus earlier stronger periods (e.g., 2020–2021), implying profitability is not yet fully translating into higher shareholder returns.
Cash Flow
74
Positive
Cash generation is solid, with TTM (Trailing-Twelve-Months) operating cash flow of ~$74.5M and free cash flow of ~$65.0M, and cash flow broadly tracking earnings (free cash flow to net income ~1.0x in TTM (Trailing-Twelve-Months)). However, free cash flow declined in TTM (Trailing-Twelve-Months) (about -11%), and cash conversion has been uneven across years (notably weaker in 2021 and stronger in 2024). Overall, cash flow is supportive, but the recent free-cash-flow step-down warrants monitoring.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue533.13M500.89M503.88M488.40M488.10M
Gross Profit237.14M223.20M221.99M215.47M222.69M
EBITDA64.88M60.68M66.58M-58.45M80.67M
Net Income21.24M16.59M17.22M-103.46M33.37M
Balance Sheet
Total Assets760.36M743.51M772.35M802.17M928.58M
Cash, Cash Equivalents and Short-Term Investments128.12M103.09M102.80M80.13M77.51M
Total Debt4.65M3.52M5.48M21.35M7.44M
Total Liabilities89.48M73.36M77.06M104.52M100.09M
Stockholders Equity670.87M670.15M695.29M697.65M828.49M
Cash Flow
Free Cash Flow59.66M68.66M45.16M40.39M21.03M
Operating Cash Flow74.50M77.83M73.27M62.08M55.24M
Investing Cash Flow-13.41M-13.58M-4.55M-43.09M-94.66M
Financing Cash Flow-40.37M-58.55M-41.86M-27.92M-22.20M

Proto Labs Technical Analysis

Technical Analysis Sentiment
Negative
Last Price54.35
Price Trends
50DMA
58.11
Negative
100DMA
54.67
Negative
200DMA
49.73
Positive
Market Momentum
MACD
-0.87
Positive
RSI
33.55
Neutral
STOCH
20.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRLB, the sentiment is Negative. The current price of 54.35 is below the 20-day moving average (MA) of 61.73, below the 50-day MA of 58.11, and above the 200-day MA of 49.73, indicating a neutral trend. The MACD of -0.87 indicates Positive momentum. The RSI at 33.55 is Neutral, neither overbought nor oversold. The STOCH value of 20.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRLB.

Proto Labs Risk Analysis

Proto Labs disclosed 35 risk factors in its most recent earnings report. Proto Labs reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Proto Labs Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
$679.20M16.919.20%7.61%25.35%
72
Outperform
$1.29B50.093.20%2.82%-34.29%
68
Neutral
$611.57M20.8113.77%3.49%22.39%112.75%
64
Neutral
$271.10M10.471.26%-3.42%
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
58
Neutral
$338.71M-47.25-3.30%-12.38%-0.71%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PRLB
Proto Labs
54.35
17.61
47.93%
IIIN
Insteel Industries
31.53
5.02
18.95%
NWPX
Northwest Pipe Company
70.94
29.10
69.55%
TG
Tredegar
7.80
0.48
6.56%
MEC
Mayville Engineering Company
16.67
2.34
16.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 07, 2026